Novartis to acquire Fougera for $1.5 billion

Novartis will acquire the dermatology generics firm Fougera for $1.53 billion in cash.  Novartis’ generic unit Sandoz is conducting the deal, and the acquisition will make Sandoz the world&…
Read the full story: InPharm